Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹240, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 17% over the past three years. New Risk • May 25
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ₹392m (US$4.1m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (188% accrual ratio). Minor Risk Revenue is less than US$5m (₹392m revenue, or US$4.1m). Valuation Update With 7 Day Price Move • May 25
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to ₹210, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years. Reported Earnings • May 20
Full year 2026 earnings released: EPS: ₹47.86 (vs ₹10.55 loss in FY 2025) Full year 2026 results: EPS: ₹47.86 (up from ₹10.55 loss in FY 2025). Revenue: ₹18.9b (up ₹18.2b from FY 2025). Net income: ₹15.5b (up ₹19.0b from FY 2025). Profit margin: 82% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • May 19
Sun Pharma Advanced Research Company Limited announced that it has received INR 1.4999645 billion in funding from Shanghvi Finance Pvt Ltd On May 19, 2026, Sun Pharma Advanced Research Company Limited has closed the transaction. Announcement • May 11
Sun Pharma Advanced Research Company Limited to Report Q4, 2026 Results on May 18, 2026 Sun Pharma Advanced Research Company Limited announced that they will report Q4, 2026 results on May 18, 2026 New Risk • Apr 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₹3.4b). Earnings have declined by 12% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change). Reported Earnings • Feb 10
Third quarter 2026 earnings released: ₹2.48 loss per share (vs ₹2.45 loss in 3Q 2025) Third quarter 2026 results: ₹2.48 loss per share (further deteriorated from ₹2.45 loss in 3Q 2025). Revenue: ₹84.5m (down 43% from 3Q 2025). Net loss: ₹804.2m (loss widened 1.1% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Announcement • Feb 03
Sun Pharma Advanced Research Company Limited to Report Q3, 2026 Results on Feb 09, 2026 Sun Pharma Advanced Research Company Limited announced that they will report Q3, 2026 results on Feb 09, 2026 Announcement • Jan 15
Sun Pharma Advanced Research Company Limited announced that it expects to receive INR 1.4999645 billion in funding from Shanghvi Finance Pvt Ltd Sun Pharma Advanced Research Company Limited announced a private placement of 38,510,000 Pre-Funded Convertible Warrants at a price per share of INR 38.95 for gross proceeds of INR 1,499,964,500 on January 14, 2026 on preferential basis. Each warrant is convertible into one fully paid-up equity share of the Company having a face value of INR 1 each, within a period of 18 (eighteen) months from the date of allotment of the Warrants, in accordance with applicable law. The transaction involves participation from returning investor Shanghvi Finance Private Limited to purchase 38,510,000 Warrants. The pre-issue equity holding of the investor is 42.28% and post-issue equity holding after exercise of the Warrants will be 48.40% with 175,721,787 equity shares of the company. New Risk • Dec 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹3.0b free cash flow). Negative equity (-₹3.4b). Earnings have declined by 14% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change). Reported Earnings • Nov 11
Second quarter 2026 earnings released: ₹2.34 loss per share (vs ₹3.31 loss in 2Q 2025) Second quarter 2026 results: ₹2.34 loss per share (improved from ₹3.31 loss in 2Q 2025). Revenue: ₹78.7m (down 39% from 2Q 2025). Net loss: ₹758.5m (loss narrowed 29% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Announcement • Oct 31
Sun Pharma Advanced Research Company Limited to Report Q2, 2026 Results on Nov 10, 2025 Sun Pharma Advanced Research Company Limited announced that they will report Q2, 2026 results at 9:08 AM, Indian Standard Time on Nov 10, 2025 Announcement • Jul 28
Sun Pharma Advanced Research Company Limited to Report Q1, 2026 Results on Aug 04, 2025 Sun Pharma Advanced Research Company Limited announced that they will report Q1, 2026 results on Aug 04, 2025 Reported Earnings • Jul 22
Full year 2025 earnings released: ₹10.55 loss per share (vs ₹11.93 loss in FY 2024) Full year 2025 results: ₹10.55 loss per share (improved from ₹11.93 loss in FY 2024). Revenue: ₹717.7m (down 5.0% from FY 2024). Net loss: ₹3.43b (loss narrowed 12% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Announcement • Jul 08
Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2025 Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2025, at 16:00 Indian Standard Time. Reported Earnings • May 21
Full year 2025 earnings released: ₹10.55 loss per share (vs ₹11.93 loss in FY 2024) Full year 2025 results: ₹10.55 loss per share (improved from ₹11.93 loss in FY 2024). Revenue: ₹735.6m (down 2.6% from FY 2024). Net loss: ₹3.43b (loss narrowed 12% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • May 12
Sun Pharma Advanced Research Company Limited to Report Q4, 2025 Results on May 19, 2025 Sun Pharma Advanced Research Company Limited announced that they will report Q4, 2025 results on May 19, 2025 New Risk • May 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹4.6b free cash flow). Negative equity (-₹774m). Earnings have declined by 14% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹4.6b free cash flow). Negative equity (-₹774m). Earnings have declined by 14% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change). Reported Earnings • Feb 11
Third quarter 2025 earnings released: ₹2.45 loss per share (vs ₹3.07 loss in 3Q 2024) Third quarter 2025 results: ₹2.45 loss per share (improved from ₹3.07 loss in 3Q 2024). Revenue: ₹151.0m (up 8.9% from 3Q 2024). Net loss: ₹795.1m (loss narrowed 20% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 21% per year. Announcement • Jan 31
Sun Pharma Advanced Research Company Limited to Report Q3, 2025 Results on Feb 10, 2025 Sun Pharma Advanced Research Company Limited announced that they will report Q3, 2025 results on Feb 10, 2025 Announcement • Jan 17
Sun Pharma Advanced Research Company Limited Announces Transfer of Venkata Palle to SPARCLIFE Inc. as Executive Vice President - Small Molecules Sun Pharma Advanced Research Company Limited announced that Dr. Venkata Palle, Executive Vice President - Global Head Drug Discovery & Preclinical Development of the Company have been transferred to SPARCLIFE Inc., Wholly Owned Subsidiary of the Company designated as Executive Vice President - Small Molecules. Reason for change: Dr. Palle is relocating to the United States (US) for personal reasons. To retain his expertise, it has been decided to transfer him to SPARCLIFE Inc., situated at Cranbury, NJ 08512. He will oversee scientific strategy and the small molecule discovery programs Additionally, it has been decided that he will no longer be a part of the Senior Management Team of the SPARC. Date of Appointment/transfer: January 17, 2025. New Risk • Nov 06
New major risk - Negative shareholders equity The company has negative equity. Total equity: -₹774m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹4.6b free cash flow). Negative equity (-₹774m). Earnings have declined by 12% per year over the past 5 years. Reported Earnings • Nov 05
Second quarter 2025 earnings released: ₹3.31 loss per share (vs ₹2.66 loss in 2Q 2024) Second quarter 2025 results: ₹3.31 loss per share (further deteriorated from ₹2.66 loss in 2Q 2024). Revenue: ₹129.0m (down 39% from 2Q 2024). Net loss: ₹1.07b (loss widened 24% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. New Risk • Nov 04
New major risk - Revenue and earnings growth Earnings have declined by 11% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹4.6b free cash flow). Earnings have declined by 11% per year over the past 5 years. Announcement • Oct 25
Sun Pharma Advanced Research Company Limited to Report Q2, 2025 Results on Nov 04, 2024 Sun Pharma Advanced Research Company Limited announced that they will report Q2, 2025 results on Nov 04, 2024 Announcement • Aug 15
Sun Pharma Advanced Research Company Limited Appoints Vidhi Dilip Shanghvi as A Non- Executive, Non-Independent Director Sun Pharma Advanced Research Company Limited at its AGM held on August 12, 2024 appointed Vidhi Dilip Shanghvi as a Non- Executive, Non-Independent Director of the Company. Announcement • Jul 29
Sun Pharma Advanced Research Company Limited to Report Q1, 2025 Results on Aug 05, 2024 Sun Pharma Advanced Research Company Limited announced that they will report Q1, 2025 results on Aug 05, 2024 Announcement • Jul 26
Sun Pharma Advanced Research Company Limited Announces Re-Designation of Nitin Dharmadhikari as Chief Operating Officer Sun Pharma Advanced Research Company Limited announced that Dr. Nitin Dharmadhikari, Senior Management Personnel of the Company has been re-designated as Chief Operating Officer (COO) of the Company effective from July 26, 2024. Dr. Nitin Dharmadhikari is Chief Operating Officer (COO). He is responsible for the various functions such as Finance, HR, IT and Quality. The COO will also be responsible for budgeting and control, managing the performance management process and compliance management. Dr. Dharmadhikari has rich experience spanning over 30 years within the pharmaceutical industry. After completing Ph.D. from Nagpur University, Dr. Dharmadhikari worked in corporates like Dr. Reddy's and Ranbaxy. He joined Sun Pharma in 1999 and looked after product development for US, Europe & India. He moved to SPARC in 2007 to oversee the drug delivery system & product development research along with Manufacturing & Quality assurance. Dr. Dharmadhikari is a co inventor of three innovative platforms and more than 50 patents /patent applications. Reported Earnings • Jul 21
Full year 2024 earnings released: ₹11.93 loss per share (vs ₹7.82 loss in FY 2023) Full year 2024 results: ₹11.93 loss per share (further deteriorated from ₹7.82 loss in FY 2023). Revenue: ₹755.5m (down 68% from FY 2023). Net loss: ₹3.87b (loss widened 74% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 6% per year. Announcement • Jul 10
Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024 Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024, at 16:00 Indian Standard Time. Reported Earnings • May 25
Full year 2024 earnings released: ₹11.93 loss per share (vs ₹7.82 loss in FY 2023) Full year 2024 results: ₹11.93 loss per share (further deteriorated from ₹7.82 loss in FY 2023). Revenue: ₹1.05b (down 56% from FY 2023). Net loss: ₹3.87b (loss widened 74% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Announcement • May 25
Sun Pharma Advanced Research Company Limited Announces Chief Financial Officer Changes The board of directors of Sun Pharma Advanced Research Company Limited at its Meeting held on May 24, 2024, accepted the resignation of Mr. Chetan Rajpara, Chief Financial Officer and Key Managerial Personnel of the Company from the services of the Company with effect from close of business hours on June 5, 2024. Appointed Mr. Anup Rathi as the Chief Financial Officer and Key Managerial Personnel of the Company with effect from June 6, 2024, as recommended by Nomination and Remuneration Committee and based on approval of the Audit Committee. Mr. Anup Rathi has spent close to 2 years in SPARC as General Manager Finance & Accounts. He has over 17 years of post- qualification work experience as a Chartered Accountant across a wide spectrum of finance functions. Prior to SPARC Mr. Anup Rathi has worked with NRB Bearings Ltd. and KEC International Ltd. (RPG Group Company) and has worked across multiple areas including Accounts, Finance, Treasury, Taxation, Investments, Banking Relationship. Anup is a Chartered Accountant (CA) and Company Secretary (CS). He holds a Bachelor's Degree in Commerce (B.com) and a Bachelor's Degree in Law (LLB). Announcement • May 19
Sun Pharma Advanced Research Company Limited to Report Q4, 2024 Results on May 24, 2024 Sun Pharma Advanced Research Company Limited announced that they will report Q4, 2024 results on May 24, 2024 Reported Earnings • Feb 06
Third quarter 2024 earnings released: ₹3.07 loss per share (vs ₹0.37 profit in 3Q 2023) Third quarter 2024 results: ₹3.07 loss per share (down from ₹0.37 profit in 3Q 2023). Revenue: ₹202.5m (down 85% from 3Q 2023). Net loss: ₹996.5m (down ₹1.10b from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings. Announcement • Jan 24
Sun Pharma Advanced Research Company Limited to Report Q3, 2024 Results on Feb 05, 2024 Sun Pharma Advanced Research Company Limited announced that they will report Q3, 2024 results on Feb 05, 2024 Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Member of Advisory Board Mark Simon was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Nov 07
Second quarter 2024 earnings released: ₹2.66 loss per share (vs ₹2.52 loss in 2Q 2023) Second quarter 2024 results: ₹2.66 loss per share (further deteriorated from ₹2.52 loss in 2Q 2023). Revenue: ₹296.7m (down 5.9% from 2Q 2023). Net loss: ₹864.2m (loss widened 26% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Announcement • Nov 03
Sun Pharma Advanced Research Company Limited Announces Retirement of Chitturi Trinadha Rao as Senior Vice President, Drug Discovery Sun Pharma Advanced Research Company Limited informed that Dr. Chitturi Trinadha Rao - Senior Vice President, Drug Discovery, retired from the Company with effect from closing of business hours of October 31, 2023. Announcement • Oct 28
Sun Pharma Advanced Research Company Limited to Report Q2, 2024 Results on Nov 06, 2023 Sun Pharma Advanced Research Company Limited announced that they will report Q2, 2024 results on Nov 06, 2023 Announcement • Sep 23
Sun Pharma Advanced Research Company Limited Appoints Kajal Damania as Company Secretary Sun Pharma Advanced Research Company Limited at its board meeting held on September 22, 2023 appointed Ms. Kajal Damania, an associate member of the Institute of the Company Secretaries of India having membership no. A29764, as the Company Secretary (Key Managerial Personnel) of the Company in accordance with the provisions of Section 203 of the Companies Act, 2013, with immediate effect i.e. September 22, 2023. Ms. Kajal Damania is an Associate Member of Institute of Company Secretaries of India (ACS 29764) and has done her post - Graduation in Commerce (Spl. Accounting & Finance); she has also done her L.L.B from Mumbai University. Ms. Kajal Damania has 15 years of experience in the field of Corporate Secretarial functions, Statutory Compliances and Corporate Commercial Laws. She has worked with Reliance Broadcast Network Ltd. and prior to this she has worked with Repro India Ltd. Announcement • Sep 13
Sun Pharma Advanced Research Company Limited Announces the Resignation of Mr. Dinesh Lahoti as Company Secretary and Compliance Officer Sun Pharma Advanced Research Company Limited announced the resignation of Mr. Dinesh Lahoti as Company Secretary and Compliance Officer, effective September 11, 2023. Announcement • Jul 29
Sun Pharma Advanced Research Company Limited to Report Q1, 2024 Results on Aug 07, 2023 Sun Pharma Advanced Research Company Limited announced that they will report Q1, 2024 results on Aug 07, 2023 Reported Earnings • Jul 20
Full year 2023 earnings released: ₹7.82 loss per share (vs ₹7.73 loss in FY 2022) Full year 2023 results: ₹7.82 loss per share (further deteriorated from ₹7.73 loss in FY 2022). Revenue: ₹2.39b (up 74% from FY 2022). Net loss: ₹2.23b (loss widened 9.4% from FY 2022). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 14
Sun Pharma Advanced Research Company Limited Announces That FDA Issues Complete Response Letter for Pdp-716 Nda Due to Inspection Findings At Third-Party Api Manufacturing Facility Sun Pharma Advanced Research Company Ltd. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PDP-716 for the treatment of patients with Glaucoma, due to inspection findings at a third-party Active Pharmaceutical Ingredient (API) manufacturing facility. The FDA did not raise any issues with the PDP-176 clinical efficacy or safety and no additional clinical data or trials have been requested. SPARC is committed to work closely with Visiox, the FDA and the third-party manufacturer to resubmit the NDA as quickly as possible. Announcement • Jul 13
Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 07, 2023 Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 07, 2023, at 15:30 Indian Standard Time. Reported Earnings • May 23
Full year 2023 earnings released: ₹7.82 loss per share (vs ₹7.73 loss in FY 2022) Full year 2023 results: ₹7.82 loss per share (further deteriorated from ₹7.73 loss in FY 2022). Revenue: ₹2.50b (up 82% from FY 2022). Net loss: ₹2.23b (loss widened 9.4% from FY 2022). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 19
Sun Pharma Advanced Research Company Limited to Report Q4, 2023 Results on May 22, 2023 Sun Pharma Advanced Research Company Limited announced that they will report Q4, 2023 results on May 22, 2023 Reported Earnings • Feb 14
Third quarter 2023 earnings released: EPS: ₹0.37 (vs ₹0.60 loss in 3Q 2022) Third quarter 2023 results: EPS: ₹0.37 (up from ₹0.60 loss in 3Q 2022). Revenue: ₹1.31b (up 111% from 3Q 2022). Net income: ₹101.5m (up ₹259.9m from 3Q 2022). Profit margin: 7.7% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 7% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 05
Sun Pharma Advanced Research Company Limited to Report Q3, 2023 Results on Feb 13, 2023 Sun Pharma Advanced Research Company Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Reported Earnings • Nov 08
Second quarter 2023 earnings released: ₹2.52 loss per share (vs ₹2.09 loss in 2Q 2022) Second quarter 2023 results: ₹2.52 loss per share (further deteriorated from ₹2.09 loss in 2Q 2022). Revenue: ₹316.0m (up 13% from 2Q 2022). Net loss: ₹684.0m (loss widened 24% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 09
First quarter 2023 earnings released: ₹3.03 loss per share (vs ₹2.34 loss in 1Q 2022) First quarter 2023 results: ₹3.03 loss per share (down from ₹2.34 loss in 1Q 2022). Revenue: ₹286.4m (up 30% from 1Q 2022). Net loss: ₹823.5m (loss widened 34% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 22
Full year 2022 earnings released: ₹7.73 loss per share (vs ₹5.77 loss in FY 2021) Full year 2022 results: ₹7.73 loss per share (down from ₹5.77 loss in FY 2021). Revenue: ₹1.37b (down 46% from FY 2021). Net loss: ₹2.03b (loss widened 35% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Reported Earnings • Feb 08
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: ₹0.60 loss per share (up from ₹2.58 loss in 3Q 2021). Revenue: ₹621.5m (up 185% from 3Q 2021). Net loss: ₹158.4m (loss narrowed 77% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings. Reported Earnings • Nov 03
Second quarter 2022 earnings released: ₹2.09 loss per share (vs ₹3.19 loss in 2Q 2021) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: ₹338.5m (up 92% from 2Q 2021). Net loss: ₹551.4m (loss narrowed 34% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Director Overboarding • Sep 20
Director Bhavna Doshi has joined 6th company board Independent Director Bhavna Doshi has been appointed to the board of KPIT Technologies Limited (NSEI:KPITTECH). Doshi now sits on a total of 6 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 20
Director Bhavna Doshi has joined 6th company board Independent Director Bhavna Doshi has been appointed to the board of KPIT Technologies Limited (NSEI:KPITTECH). Doshi now sits on a total of 6 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 20
Director Bhavna Doshi has joined 6th company board Independent Director Bhavna Doshi has been appointed to the board of KPIT Technologies Limited (NSEI:KPITTECH). Doshi now sits on a total of 6 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 20
Director Bhavna Doshi has joined 6th company board Independent Director Bhavna Doshi has been appointed to the board of KPIT Technologies Limited (NSEI:KPITTECH). Doshi now sits on a total of 6 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 20
Director Bhavna Doshi has joined 6th company board Independent Director Bhavna Doshi has been appointed to the board of KPIT Technologies Limited (NSEI:KPITTECH). Doshi now sits on a total of 6 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 20
Director Bhavna Doshi has joined 6th company board Independent Director Bhavna Doshi has been appointed to the board of KPIT Technologies Limited (NSEI:KPITTECH). Doshi now sits on a total of 6 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 20
Director Bhavna Doshi has joined 6th company board Independent Director Bhavna Doshi has been appointed to the board of KPIT Technologies Limited (NSEI:KPITTECH). Doshi now sits on a total of 6 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 19
Director Bhavna Doshi has joined 6th company board Independent Director Bhavna Doshi has been appointed to the board of KPIT Technologies Limited (NSEI:KPITTECH). Doshi now sits on a total of 6 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 19
Director Bhavna Doshi has joined 6th company board Independent Director Bhavna Doshi has been appointed to the board of KPIT Technologies Limited (NSEI:KPITTECH). Doshi now sits on a total of 6 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Reported Earnings • Jul 28
First quarter 2022 earnings released: ₹2.34 loss per share (vs ₹2.16 profit in 1Q 2021) The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: ₹219.9m (down 88% from 1Q 2021). Net loss: ₹613.7m (down 208% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 13% per year. Reported Earnings • May 19
Full year 2021 earnings released: ₹5.77 loss per share (vs ₹11.92 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: ₹2.58b (up 236% from FY 2020). Net loss: ₹1.51b (loss narrowed 52% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Feb 25
New 90-day low: ₹168 The company is down 7.0% from its price of ₹182 on 27 November 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Reported Earnings • Feb 10
Third quarter 2021 earnings released: ₹2.58 loss per share (vs ₹2.12 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: ₹218.1m (up 11% from 3Q 2020). Net loss: ₹676.2m (loss widened 22% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Jan 01
New 90-day high: ₹197 The company is up 14% from its price of ₹173 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Is New 90 Day High Low • Dec 01
New 90-day high: ₹185 The company is up 4.0% from its price of ₹179 on 02 September 2020. The Indian market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Reported Earnings • Nov 11
Second quarter 2021 earnings released: ₹3.19 loss per share The company reported a soft second quarter result with increased losses and weaker control over expenses, although revenues were improved. Second quarter 2021 results: Revenue: ₹204.6m (up 19% from 2Q 2020). Net loss: ₹834.9m (loss widened 32% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 29
New 90-day low: ₹165 The company is down 6.0% from its price of ₹176 on 31 July 2020. The Indian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. 